Controlled release system for pulmonary delivery of surfactant protein d

Abstract

A controlled release system including surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition including the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.

1 . A controlled release system in the form of a nanoparticle that provides controlled release of biologically active surfactant protein D (SPD), said nanoparticle comprising biologically active SPD and a polymeric carrier selected from the group consisting of polylactic-co-glycolic acid (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), chitosan, polycaprolactone, and poly-alkyl cyanoacrylates, wherein said system does not comprise surfactant components other than said SPD. 
     
     
         3 . (canceled) 
     
     
         4 . The system according to  claim 1 , wherein said polymer carrier is polylactic-co-glycolic acid (PLGA). 
     
     
         5 . The system according to  claim 4 , wherein the ratio of lactic acid to glycolic acid in said PLGA is selected from the group consisting of 50:50, 65:35, 70:30, 75:25, 82:18 and 85:15. 
     
     
         10 . (canceled) 
     
     
         11 . The system according to  claim 1 , further comprising and a pharmaceutically acceptable carrier. 
     
     
         12 . The system according to  claim 1 , in the form of an aerosol. 
     
     
         13 . The system according to  claim 1 , wherein the SPD is the sole active agent in the nanoparticle. 
     
     
         14 . (canceled) 
     
     
         15 . A method for the treatment of a disease, disorder or condition selected from the group consisting of chronic obstructive lung disease (COPD), asthma, acute bronchitis, chronic bronchitis, bronchopulmonary dysplasia, emphysema, infant respiratory distress syndrome (IRDS), acute respiratory distress syndrome (ARDS), lung infections, persistent pulmonary hypertension, lung hypoplasia, cancer, cystic fibrosis, alveolar proteinosis, upper respiratory inflammation, congenital SP-B deficiency, respiratory syncytial virus (RSV), allergic rhinitis, influenza, and a disease, disorder or condition associated with a decreased level of SPD in a subject, comprising administering the system according to  claim 1  to said subject. 
     
     
         16 . A method for pulmonary delivery of SPD comprising administering to a subject in need thereof the system according to  claim 1 . 
     
     
         17 . The method of  claim 15 , wherein said disease, disorder or condition is selected from the group consisting of chronic obstructive lung disease (COPD), asthma, bronchopulmonary dysplasia, emphysema, infant respiratory distress syndrome (IRDS), acute respiratory distress syndrome (ARDS), persistent pulmonary hypertension, lung hypoplasia, cancer, cystic fibrosis, alveolar proteinosis, and congenital SP-B deficiency.